全文获取类型
收费全文 | 218910篇 |
免费 | 20874篇 |
国内免费 | 14971篇 |
专业分类
耳鼻咽喉 | 2286篇 |
儿科学 | 2735篇 |
妇产科学 | 1896篇 |
基础医学 | 21271篇 |
口腔科学 | 3973篇 |
临床医学 | 27348篇 |
内科学 | 28059篇 |
皮肤病学 | 2522篇 |
神经病学 | 8895篇 |
特种医学 | 7963篇 |
外国民族医学 | 99篇 |
外科学 | 22435篇 |
综合类 | 45617篇 |
现状与发展 | 65篇 |
一般理论 | 24篇 |
预防医学 | 18185篇 |
眼科学 | 5230篇 |
药学 | 23312篇 |
255篇 | |
中国医学 | 15863篇 |
肿瘤学 | 16722篇 |
出版年
2024年 | 835篇 |
2023年 | 3132篇 |
2022年 | 8080篇 |
2021年 | 10563篇 |
2020年 | 8255篇 |
2019年 | 6350篇 |
2018年 | 6932篇 |
2017年 | 6844篇 |
2016年 | 6405篇 |
2015年 | 10304篇 |
2014年 | 12541篇 |
2013年 | 12592篇 |
2012年 | 18124篇 |
2011年 | 19552篇 |
2010年 | 14618篇 |
2009年 | 12135篇 |
2008年 | 13760篇 |
2007年 | 13295篇 |
2006年 | 12701篇 |
2005年 | 11103篇 |
2004年 | 7922篇 |
2003年 | 7437篇 |
2002年 | 6116篇 |
2001年 | 4808篇 |
2000年 | 3937篇 |
1999年 | 3333篇 |
1998年 | 2041篇 |
1997年 | 1928篇 |
1996年 | 1484篇 |
1995年 | 1424篇 |
1994年 | 1139篇 |
1993年 | 691篇 |
1992年 | 760篇 |
1991年 | 653篇 |
1990年 | 582篇 |
1989年 | 466篇 |
1988年 | 398篇 |
1987年 | 388篇 |
1986年 | 272篇 |
1985年 | 224篇 |
1984年 | 122篇 |
1983年 | 80篇 |
1982年 | 55篇 |
1981年 | 65篇 |
1980年 | 28篇 |
1979年 | 63篇 |
1977年 | 20篇 |
1976年 | 18篇 |
1974年 | 22篇 |
1973年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的:对应用低分子肝素钙与奥扎格雷联合对患有脑血栓疾病的患者实施治疗的临床效果进行研究。方法整群选择在该院2012年12月—2014年12月就诊的患有脑血栓疾病的患者86例,随机分为对照组和治疗组,每组43例。采用奥扎格雷对对照组患者实施治疗;采用低分子肝素钙与奥扎格雷联合对治疗组患者实施治疗。对比神经功能缺损评分在药物治疗前后的变化幅度、脑神经功能恢复正常时间和脑血栓药物治疗计划实施总时间、脑血栓疾病药物治疗效果、用药期间的不良反应人数。结果治疗组患者神经功能缺损评分在药物治疗前后的变化幅度明显大于对照组;脑神经功能恢复正常时间(9.66±2.41)d和脑血栓药物治疗计划实施总时间(13.28±2.14)d明显短于对照组(13.62±3.47)、(17.39±3.20)d;脑血栓疾病药物治疗效果(总有效率90.6%)明显优于对照组(总有效率69.8%);用药期间的不良反应人数(1例)明显少于对照组(8例)。结论应用低分子肝素钙与奥扎格雷联合对患有脑血栓疾病的患者实施治疗的临床效果非常明显。 相似文献
2.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis 下载免费PDF全文
3.
4.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
5.
6.
7.
8.
Tian-Yuan Xiong Fang-Yang Huang Qi Liu Yong Peng Yuan-Ning Xu Jia-Fu Wei 《Annals of medicine》2020,52(7):361-366
Abstract
Background
Comorbidities are commonly seen in patients with coronavirus disease 2019 (COVID-19), but the clinical implication is not yet well-delineated. We aim to characterize the prevalence and clinical implications of comorbidities in patients with COVID-19. 相似文献9.
10.
Ling Zhang Xue-Jun Shang Hong-Fei Li Yu-Qin Shi Wei Li Maria E Teves Zhi-Qiong Wang Gao-Feng Jiang Shi-Zhen Song Zhi-Bing Zhang 《Asian journal of andrology》2015,17(1):86-93
Mammalian spermatogenesis is a well-organized process of cell development and differentiation. Meiosis expressed gene 1 (MEIG1) plays an essential role in the regulation of spermiogenesis. To explore potential mechanisms of MEIG1''s action, a yeast two-hybrid screen was conducted, and several potential binding partners were identified; one of them was membrane occupation and recognition nexus repeat containing 3 (MORN3). MORN3 mRNA is only abundant in mouse testis. In the testis, Morn3 mRNA is highly expressed in the spermiogenesis stage. Specific anti-MORN3 polyclonal antibody was generated against N-terminus of the full-length MORN3 protein, and MORN3 expression and localization was examined in vitro and in vivo. In transfected Chinese hamster ovary cells, the antibody specifically crossed-reacted the full-length MORN3 protein, and immunofluorescence staining revealed that MORN3 was localized throughout the cytoplasm. Among multiple mouse tissues, about 25 kDa protein, was identified only in the testis. The protein was highly expressed after day 20 of birth. Immunofluorescence staining on mixed testicular cells isolated from adult wild-type mice demonstrated that MORN3 was expressed in the acrosome in germ cells throughout spermiogenesis. The protein was also present in the manchette of elongating spermatids. The total MORN3 expression and acrosome localization were not changed in the Meig 1-deficient mice. However, its expression in manchette was dramatically reduced in the mutant mice. Our studies suggest that MORN3 is another regulator for spermatogenesis, probably together with MEIG1. 相似文献